

TABLE OF CONTENTS

1.	General Data on the Irradiated Patient.....	6
1.1	Demographic Data	6
1.2	Occupation at the Time of the Accident.....	6
1.3	History at the Time of the Accident.....	7
1.4	Institutions Involved in Patient Care and Database Recording.....	7
1.4.1	Primary Care Institution Keeping the Patient's Medical Records	7
1.4.2	Definitive Care Institution	7
1.4.3	Physician Submitting the Case to the Registry.....	7
1.4.4	Source of Compilation.....	7
2.	Accident Information and Personal Exposure Conditions.....	8
2.1	Accident Description	8
2.1.1	Country.....	8
2.1.2	City	8
2.1.3	Location (Factory etc.) of the Accident.....	8
2.1.4	Begin and End of the Accident.....	8
2.1.5	Proprietor of the Radiation Source.....	8
2.1.6	General Description of the Accident	8
2.1.7	Number of Persons Involved.....	9
2.1.8	IAEA Nuclear Event Scale	9
2.2	Source of Irradiation	9
2.2.1	Critical Chain Reaction.....	9
2.2.2	Reactor Accident with Consecutive Emission	9
2.2.3	Nuclear Explosion	9
2.2.4	Sealed Source.....	9
2.2.5	Unsealed Source.....	10
2.2.6	X-ray Equipment	10
2.2.7	Accelerators	10
2.2.8	Other Sources than 2.2.1 - 2.2.7	10
2.3	Personal Exposure Conditions.....	10
2.3.1	Begin and End of Exposure	10
2.3.2	Individual Description of the Accident.....	10
2.3.3	External Irradiation	11
2.3.4	External Contamination	12
2.3.5	Internal Contamination	12
2.3.6	Evaluation of the Average Total Body Dose	13
2.3.7	Evaluation of Local Doses	13
2.3.8	Evaluation of Doses of Internal Exposure.....	14
3	Clinical Data After Exposure	14
3.1	Primary Reaction.....	14
3.1.1	Dyspeptic Symptoms and Enlargement of Parotid Glands.....	14
3.1.2	Primary Skin Erythema and Hyperaemia of Mucous Membranes.....	15
3.1.3	General Neurocirculatory Symptoms and Signs.....	15
3.2	Involvement of the Nervous System and the Eyes	15
3.2.1	Diagnostic Procedures for Central and Peripheral Nervous System.....	15
3.2.2	Impairment of Central and Peripheral Nervous System	16
3.2.3	Lesions of Eyes.....	20

3.3	Radiation Induced Lesions of Skin, its Appendices, and Underlying Tissues	22
3.3.1	Diagnostic Procedures.....	22
3.3.2	Radiation Induced Skin Lesions.....	22
3.3.3	Disturbances of Nails	23
3.3.4	Epilation.....	23
3.3.5	Amputation of Extremities	24
3.3.6	Debridement of Necrotic Tissue.....	24
3.3.7	Reconstructive Surgery due to Dermal Radiation Lesions	24
3.4	Bone Marrow Syndrome and Blood	25
3.4.1	Peripheral Blood Count	26
3.4.2	Peripheral Blood Smear	32
3.4.3	Bone Marrow Examination	38
3.4.4	Cytogenetic Data.....	39
3.4.5	Biochemical Data	40
3.4.6	Haemostatic Parameters	44
3.4.7	Immunological and Immunohaematological Tests	46
3.4.8	Microbiological Analysis.....	50
3.4.9	Lesions of Bone Marrow	54
3.5	Radiation Induced Lesions of Gastrointestinal Tract	56
3.5.1	Diagnostic Procedures.....	56
3.5.2	Faeces Analysis	56
3.5.3	Radiation Mucositis	57
3.5.4	Acute Gastrointestinal Syndrome	57
3.5.5	Stool Characteristics	58
3.6	Organs Especially Sensitive Under Certain Exposure Conditions	59
3.6.1	Lesions of Upper Respiratory Tract and Lung	59
3.6.2	Lesions of the Thyroid Gland	62
3.6.3	Pregnancy.....	63
3.7	Lesions of Other Organs	63
3.7.1	Lesions of the Kidneys	63
3.7.2	Lesions of the Liver	66
3.7.3	Evaluation of Male Reproductive Function	66
3.7.4	Evaluation of Female Reproductive Function	67
3.7.5	Lesions of Cardio-Vascular System.....	67
3.7.6	General Physiological Parameters.....	69
4.	Treatment and Drugs	70
4.1	Individual Radiation Protection Measures	70
4.1.1	Application of Personal Radiation Protectants during the Accident.....	70
4.1.2	Methods (Drugs) of Early Pathogenetical Treatment.....	70
4.1.3	Decontamination Measures	70
4.1.4	Decorporation Measures.....	71
4.2	Physical Methods of Treatment.....	71
4.2.1	Hospitalisation and Protective Environment	71
4.2.2	Locally Reversed Isolation for Burn Treatment.....	71
4.3	Substituting Therapy by Blood and Blood Products.....	72
4.3.1	Irradiation of Blood and Blood Products.....	72
4.3.2	Blood Groups and Alloimmunisation	72
4.3.3	Whole Blood Transfusions	73
4.3.4	Red Blood Cell Transfusions	74
4.3.5	Platelet Transfusions and Thrombocytopheresis.....	74
4.3.6	White Blood Cell Transfusions.....	75
4.3.7	Plasma Transfusions and Plasmapheresis.....	76
4.3.8	Albumin Solution Infusions, Gamma Globulin Substitution and Other Blood Components	77

4.4	Drugs.....	77
4.5	Haemostimulators	82
4.5.1	Myelopoietic Growth Factors	82
4.5.2	Other Growth Factors	82
4.5.3	Drugs as Leucostimulators	82
4.6	Haemopoietic Stem Cell Transplantation	82
5.	Clinical Status at the Time of Reporting	82
5.1	Survival Status	82
5.1.1	General Information on the Survival Status	82
5.1.2	Loss of Follow-Up	82
5.1.3	Death of Patient.....	83
5.1.4	Causes of Death	83
5.2	Clinical Status.....	84
5.2.1	Time of Evaluation.....	84
5.2.2	Radiation Related Persisting Haemopoietic Disorders	84
5.2.3	Other Persisting Haemopoietic Disorders.....	84
5.2.4	Radiation Related Persisting Lesions of Skin and Underlying Tissue	85
5.2.5	Other Persisting Lesions of Skin and Underlying Tissue.....	85
5.2.6	Radiation Related Persisting Lesions of Other Organs	85
5.2.7	Additional Persisting Lesions of Other Organs	86
5.3	Functional Status.....	86
5.3.1	Time of Evaluation.....	86
5.3.2	Karnofsky Performance Score.....	86
5.3.3	Rehabilitation.....	86
6.	Skin Burns	87
6.1	Burn Score	87
6.2	Localisation Coding - Total Body, Head, Neck and Upper Trunk	87
6.3	Localisation Coding - Arms, Lower Trunk.....	88
6.4	Localisation Coding - Lower Trunk, Legs.....	89
6.5	Skin Burns	92
7.	Haematopoietic Stem Cell Transplantation	93
7.1	Source of Stem Cells	93
7.2	Type of Transplantation.....	93
7.3	Histocompatibility Tests for Allogeneic Transplantation.....	93
7.3.1	Typing.....	93
7.3.2	Donor and Recipient Cells Were Tested for Matching.....	94
7.4	Donor Information.....	94
7.4.1	Donor's Demographical Data	94
7.4.2	Donor Relationship and Alloimmunisation History	94
7.4.3	Donor had Serological Evidence of Previous Viral Exposure or Infection	95
7.5	Transplant Manoeuvre	95
7.5.1	Conditioning Therapy prior to Stem Cell Therapy	95
7.5.2	Cells Were Manipulated or Concentrated in vitro	95

7.6	Drugs to Prevent Acute Graft-versus-Host Disease (GvHD)	95
7.7	In vitro and in vivo Removal of Donor T Cells to Prevent GvHD	96
7.8	Evidence for Haemopoietic Engraftment.....	96
7.9	Overall Evaluation of Engraftment	97
7.10	Graft-versus-Host Disease	97
7.11	Specific Therapy for GvHD	97
8.	Annexes	98
8.1	IAEA International nuclear event scale	98
8.2	Conversion of Non-SI to SI Units	99
8.3	Orders of Magnitude.....	99
8.4	Karnofsky Scale for Rating Activity Status	99
8.5	References	100
8.6	Normal Values of Laboratory Parameters.....	101
8.7	Pages for copying	109
8.7.1	Symptoms and Signs	109
8.7.2	Laboratory Values (left & right)	110
8.7.3	Normal Values.....	112
8.7.4	Antibiogramm (left)	113
8.7.5	Antibiogramm (right).....	114